Two months ago, biotechnology startup Good Therapeutics struck it big.
A cancer immunotherapy the company was working on drew such interest from Roche that the Swiss pharmaceutical giant paid $250 million, far more than the $30 million the startup had raised privately, to buy it outright.
But Good and its management team only parted with one piece of their work. They kept the technology that led to that drug prospect and turned it into a new company.
